Cite
HARVARD Citation
Martin-Blondel, G. et al. (2022). Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Journal of infection. 84 (6), pp. e101-e104. [Online].